Overview
DBVT market data
Price History
DBVT price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.05 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.60 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.45 – $4.50 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $702.7 · P/B 4.47 · P/S 141.93.
Company news
DBV Technologies dépose un prospectus relatif à son Programme At-The-Market (ATM) pour un montant pouvant atteindre 150 millions de dollarsGlobenewswire Inc · Jul 17, 2026, 9:15 PM
DBV Technologies Q2 EPS $(0.12) Misses $(0.10) Estimate, Sales $700.000K Miss $1.391M EstimateBenzinga · Jul 16, 2026, 8:03 PM
Citizens Maintains Market Outperform on DBV Technologies, Raises Price Target to $55Benzinga · Jun 30, 2026, 2:20 PM
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for FilingGlobenewswire Inc · Jun 29, 2026, 8:15 PM
DBV Technologies fait le point sur le dépôt du dossier BLA pour le patch VIASKIN® Peanut chez les enfants âgés de 4 à 7 ans; la Société travaille en collaboration avec la FDA afin d'optimiser le processus d'examen en vue du dépôt du dossierGlobenewswire Inc · Jun 29, 2026, 8:15 PM
DBV Technologies révise sa participation à la 47ème conférence annuelle Global Healthcare organisée par Goldman SachsGlobenewswire Inc · Jun 9, 2026, 11:15 AM
DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare ConferenceGlobenewswire Inc · Jun 9, 2026, 11:15 AM
DBV Technologies présente de nouvelles données positives issues de l’étude de phase 3 VITESSE, et un aperçu de l’étude THRIVE récemment initiée à l’occasion du Congrès de l’EAACI 2026Globenewswire Inc · Jun 8, 2026, 9:15 PM
DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026Globenewswire Inc · Jun 8, 2026, 9:15 PM
DBV Technologies To Present New Data From VITESSE Study And Preview Recently Initiated THRIVE Study At EAACI Congress 2026Benzinga · Jun 8, 2026, 8:45 PM